Prof. F. Brombacher* studied Biology, with Diploma in Genetics, 1989 at the Alberts-Ludwigs University Freiburg, Germany; PhD in Molecular Immunology at the Max Planck Institute (MPI), 1989, pioneering transgenic mouse models in the group of Nobel Laureate G. Koehler. Subsequent Research Fellow at MPI and Sandoz Ag (now Novartis), Switzerland, he was called back to the MPI as Group Leader in 1994, working on infectious diseases using knockout mouse models.
1998, he moved to the University of Cape Town, South Africa, as Professor, and A-rated by NRF, was awarded an extramural MRC Unit and an International Wellcome Trust Senior Research Fellow in 2000. Thereafter, Fellow for Life at UCT in 2005 and South African Research Chair and Coordinator at ICGEB Cape Town component. His group investigates fundamental immunological mechanisms in human diseases, including tuberculosis, African trypanosomiasis, leishmaniasis and helminthic infections, including bilharzia – four of the top ten WHO declared human threats to combat, in addition to chronic diseases like allergic asthma and colitis. His research strategy is based on knowledge by gain or loss of function approaches in animal models. Together with transcriptomics and proteomics approaches biomarkers and host-directed drug targets are identified and verified in humans. His H factor is 65 with more than 18000 citation and 197 international peer-reviewed publications.
*International Center for Genetic Engineering and Biotechnology (ICGEB), Cape Town Component and Institute of Infectious Diseases and Molecular Medicine (IDM), Division of Immunology, University of Cape Town, South Africa